Entrada Therapeutics filings document a clinical-stage biopharmaceutical issuer developing genetic medicines that engage intracellular targets. Recent Form 8-K reports furnish quarterly and annual financial results, cash and marketable-securities updates, and corporate updates related to its Duchenne muscular dystrophy franchise, ocular disease pipeline and partnered VX-670 program for myotonic dystrophy type 1.
Proxy materials describe annual meeting matters, including director elections, auditor ratification and amendments to the company’s stock option and employee stock purchase plans. The filings also identify TRDA common stock listed on The Nasdaq Global Market, emerging growth company status, Regulation FD disclosures and governance matters tied to equity compensation and stockholder voting.
Entrada Therapeutics, Inc. reports that a group of MPM BioVentures funds and related entities, together with Ansbert Gadicke, Luke Evnin and Todd Foley, collectively beneficially own 3,885,115 shares of common stock, representing 9.98% of the outstanding shares as of July 31, 2026.
The shares are held across several Delaware limited partnerships and LLCs, including BV 2014, BV 2014(B), AM BV2014 LLC, BV 2018, BV 2018(B) and AM BV2018 LLC, with associated GP and management entities deemed to share voting and dispositive power. The amendment is dated September 8, 2026 and notes that individual percentage figures in the cover tables are rounded to 9.9% due to EDGAR field limits.
Entrada Therapeutics, Inc. (TRDA) had common stock sales reported by investment funds affiliated with MPM BioVentures, which are ten percent owners. On September 4, 2026, affiliated funds sold 38,500 shares at a weighted average price of $7.11 per share, with individual sale prices ranging from $7.01 to $7.16. On September 8, 2026, they sold 192,500 shares at a weighted average price of $7.41 per share, with sale prices between $6.97 and $7.70. On September 9, 2026, they sold an additional 28,837 shares at a weighted average price of $7.13, with sale prices between $7.02 and $7.54. After the last reported sale, the funds continued to hold large positions, including 1,764,167 shares held by MPM BioVentures 2014, L.P. and 1,810,592 shares held by MPM BioVentures 2018, L.P. The reporting persons state that each of them disclaims beneficial ownership of the securities except to the extent of their respective pecuniary interest and no Rule 10b5-1 trading plan is reported.
Entrada Therapeutics, Inc. (TRDA) reported that investment funds affiliated with MPM BioVentures, which are ten percent owners, made indirect open-market sales of an aggregate 259,837 shares of Common Stock over three days in September 2026. The sales were executed at weighted average prices between roughly $7.01 and $7.70 per share, with the shares held across multiple MPM partnerships and LLCs. Each reporting person disclaims beneficial ownership beyond its pecuniary interest, and no Rule 10b5-1 trading plan is reported.
Entrada Therapeutics, Inc. (TRDA) reported that investment entities affiliated with MPM BioVentures, including MPM BioVentures 2018, L.P. and related funds, sold a total of 86,482 shares of Common Stock in open-market transactions on September 1–3, 2026. Daily sales were 29,088 shares at a weighted average price of about $7.06 on September 1, 25,131 shares at about $7.19 on September 2, and 32,263 shares at about $7.17 on September 3, each within the price ranges disclosed in the notes. The shares are held across multiple MPM limited partnerships and LLCs, and each reporting person disclaims beneficial ownership except to the extent of its pecuniary interest. No Rule 10b5-1 trading plan is reported for these transactions.
Entrada Therapeutics, Inc. (TRDA) had affiliated investment funds jointly report open-market or private sales of a total of 86,482 shares of common stock on September 1–3, 2026, at weighted average prices of about $7.06, $7.19 and $7.17 per share, all held indirectly through MPM BioVentures entities, which each reporting person disclaims beneficial ownership of except for its pecuniary interest.
Entrada Therapeutics, Inc. (TRDA) director and CEO Dipal Doshi reported a Form 4 transaction involving 8,724 shares of common stock on September 2, 2026. The shares were disposed of at a weighted average price of $7.1439 under a mandatory sell-to-cover provision to satisfy minimum statutory tax withholding obligations and did not represent a discretionary trade. After this tax-withholding disposition, Doshi directly holds 517,290 shares of Entrada Therapeutics common stock.
Entrada Therapeutics, Inc. (TRDA) reported that its President & COO, Nathan J. Dowden, had 2,528 shares of common stock disposed of on September 2, 2026 to satisfy minimum statutory tax withholding obligations. The shares were automatically sold by the company under a mandatory sell-to-cover provision and were not a discretionary trade. After this withholding-related sale, Dowden directly holds 196,060 shares of Entrada Therapeutics common stock.
Entrada Therapeutics, Inc. (TRDA) reported that Sethuraman Natarajan, its President, Research & Develop., had 2,079 shares of common stock disposed of on September 2, 2026 to satisfy minimum statutory tax withholding obligations. The shares were automatically sold by the company under a mandatory sell-to-cover provision and were not a discretionary trade by the insider. Following this tax-withholding transaction, Natarajan directly holds 214,238 shares of Entrada Therapeutics common stock.
Entrada Therapeutics, Inc. (TRDA) reported that its Chief Financial Officer, Kory James Wentworth, had 1,733 shares of common stock disposed of on September 2, 2026 to satisfy minimum statutory tax withholding obligations. The shares were automatically sold by the company under a mandatory sell-to-cover provision and were not a discretionary trade. After this tax-withholding transaction, the CFO directly held 117,277 shares of Entrada Therapeutics common stock.
Entrada Therapeutics, Inc. (TRDA) reported that investment entities affiliated with MPM BioVentures, including MPM BioVentures 2018, L.P., MPM BioVentures 2018 LLC and MPM BioVentures 2018 GP LLC as ten percent owners, conducted open‑market sales of Entrada common stock. Over August 27–31, 2026, these affiliated funds sold an aggregate 86,914 shares indirectly held, in three transactions of 38,922; 3,733; and 44,259 shares, at weighted average prices around $7 per share within disclosed price ranges. The shares are held across several MPM BioVentures funds, and each reporting person disclaims beneficial ownership except to the extent of its pecuniary interest. The Rule 10b5‑1 trading plan checkbox was not marked as applicable.